Login

Financial Snapshot

Revenue
TTM
$148.2K
Gross Margin
TTM
38.45%
Net Income
TTM
-$12.26M
Current Assets
2024 Q2
Current Liabilities
2024 Q2
Current Ratio
2024 Q2
9.97%
Total Assets
2024 Q2
Total Liabilities
2024 Q2
$13.96M
Book Value
2024 Q2
-$12.56M
Cash
2024 Q2
P/E
Last 4 Quarters
N/A
Free Cash Flow
TTM
-$1.229M

Stock Price

Loading...
Market Cap: $0.00

About Arch Therapeutics, Inc.

Arch Therapeutics, Inc. is a biotechnology company developing and marketing products based on its AC5 self-assembling technology platform. These products can be advances in the field of stasis and barrier applications. The Company’s flagship products and product candidates are derived from its AC5 self-assembling peptide (SAP) technology platform and referred to as AC5 or the AC5 Devices. These include AC5 Advanced Wound System and AC5 Topical Hemostat, which are intended for skin applications, such as management of complicated chronic wounds and acute surgical wounds. Other products are in development for use in minimally invasive or open surgical procedures and include AC5-GTM for gastrointestinal endoscopic procedures and AC5-V and AC5 Surgical Hemostat for hemostasis inside the body. It is developing BioSurgery products for internal use, including for hemostasis and sealant applications, and gastrointestinal endoscopic surgical procedures.

Industry: Surgical & Medical Instruments & Apparatus Peers: Nexgel Inc CHEMBIO DIAGNOSTICS, INC. Rapid Therapeutic Science Laboratories, Inc. PROCYON CORP /entities/skya Vycor Medical Inc

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support